Anti-anginal Drug Class List

Drugs in Drug Class: Anti-anginal

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mankind Pharma	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	212284-001	Feb 12, 2020	AB	RX	No	No
Glenmark Pharms Ltd	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	211082-001	Jul 5, 2019	AB	RX	No	No
Hetero Labs Ltd Iii	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	212788-001	May 5, 2022	AB	RX	No	No

Market Dynamics and Patent Landscape for Anti-Anginal Drugs

Last updated: July 28, 2025

Introduction

The anti-anginal drug class encompasses a broad spectrum of pharmaceuticals designed to alleviate anginal symptoms, primarily through improving myocardial oxygen supply-demand balance. These drugs play a critical role in managing chronic coronary artery disease and ischemic heart conditions, which remain significant global health concerns. As the market evolves with technological advancements and regulatory changes, understanding the current market dynamics and patent landscape becomes essential for stakeholders aiming to navigate opportunities and challenges in this therapeutic area.

Market Overview of Anti-Anginal Drugs

The global anti-anginal market has demonstrated steady growth over the past decade, driven by increasing prevalence of cardiovascular diseases (CVD), aging populations, and advancements in drug development. According to industry reports, the market size was valued at approximately USD 12 billion in 2021, with projections reaching USD 17 billion by 2030, growing at a CAGR of about 4.5% (1).

The therapeutic agents within this class include nitrates, beta-blockers, calcium channel blockers, ranolazine, and other emerging agents. Traditional drugs like nitroglycerin remain front-line therapies for acute anginal episodes, whereas newer agents focus on maintaining long-term control and reducing adverse effects.

Drivers of Market Growth

• Rising CVD prevalence: An aging global population and lifestyle factors like obesity and smoking contribute to increased angina cases.
• Innovation and drug pipeline: The introduction of novel agents and formulation improvements enhances treatment efficacy.
• Healthcare infrastructure: Enhanced diagnostic capabilities and awareness lead to earlier detection and management of angina.
• Regulatory support: Incentives for cardiovascular drug development and approval pathways promote innovation.

Market Challenges

• Generic competition: Many established drugs, such as nitrates and beta-blockers, face patent expirations, increasing price competition.
• Pricing pressures: Cost-containment policies and reimbursement constraints impact profitability.
• Adherence issues: Complex dosing regimens and side effects reduce patient compliance, affecting overall market growth.

Patent Landscape in Anti-Anginal Drugs

Patents serve as vital intellectual property rights that underpin commercial viability, incentivize innovation, and influence market exclusivity. The anti-anginal market comprises a mixture of blockbuster branded drugs, generics, and novel entities, with patent expiry significantly shaping competitive dynamics.

Key Patents and Their Lifespans

Historically, many primary patents covering standard anti-anginal agents such as nitrates, calcium channel blockers, and beta-blockers have expired or are nearing expiration. For example, the patent protection for certain formulations of amlodipine and ranolazine concluded around 2019–2022, opening the market to generic entrants (2).

Newer agents, including phosphodiesterase inhibitors and novel formulations, continue to hold patent protection, providing periods of market exclusivity lasting 10–15 years from filing. Patent filings tend to focus on:

• Novel chemical entities (NCEs): Designed to improve efficacy or reduce side effects.
• Method-of-use patents: Covering specific indications or combination therapies.
• Formulation patents: Enhancing drug delivery, stability, or patient compliance.

Innovative Patents and Recent Developments

The patent landscape reflects ongoing innovation centered around:

• Ranolazine derivatives: Several patents aim to extend its clinical utility beyond angina, targeting arrhythmias and heart failure.
• Long-acting formulations: Patent estates are actively protecting modified-release formulations to improve adherence.
• Combination therapies: Patents covering fixed-dose combinations (FDCs) that integrate anti-anginal agents with other cardiovascular drugs, reducing pill burden and improving outcomes.

Impact of Patent Expirations

Patent cliffs for key drugs have facilitated a wave of generic entry, exerting downward pressure on prices and reducing the market share of branded drugs. However, firms continue to innovate through patent-protected new agents and formulations, maintaining competitive advantages.

Legal and Regulatory Considerations

Patent challenges, such as patent oppositions and litigation, are common in this segment, especially surrounding secondary patents that can delay generic entry. Regulatory pathways, including 505(b)(2) filings, allow for expedited approval of modified formulations, extending market exclusivity.

Market Dynamics Influenced by Patent Strategies

The strategic use of patent portfolios influences pricing, market entry timing, and lifecycle management. Companies often employ "patent thickets"—overlapping patent protections—to defend against generic competition. Conversely, aggressive patent litigation can delay generics but may impact long-term market perceptions and profitability.

Future Outlook of the Anti-Anginal Patent Landscape

Emerging trendlines suggest a focus on:

• Biologics and biosimilars: Although less prominent currently, biologic therapies for ischemic heart conditions could influence future patent strategies.
• Personalized medicine: Genomic and biomarker-driven approaches may lead to targeted anti-anginal therapies with distinct patent considerations.
• Digital health integration: Patent protection for digital adherence tools and remote monitoring devices may become integral to comprehensive angina management.

Conclusion

The anti-anginal drug market is characterized by a mixture of legacy drugs facing patent expiries and innovative agents protected by new patents. The landscape is shaped by strategic patent filings, legal challenges, and regulatory incentives, influencing market competition, pricing, and access.

Stakeholders must continuously monitor patent expirations and filings, leverage innovation in formulations and combinations, and navigate IP challenges to optimize competitive advantage. Sustained innovation, combined with strategic patent management, remains critical for long-term success in this dynamic therapeutic landscape.

Key Takeaways

• The anti-anginal market is evolving alongside a substantial patent expiry wave, catalyzing competition from generics.
• Innovation in formulations, combinations, and novel chemical entities sustains patent protection and market exclusivity.
• Strategic patent filings are key to extending product lifecycle and defending against generic competition.
• Emerging trends include biologics, personalized therapies, and digital health solutions, which may redefine patent strategies.
• Monitoring patent landscapes enables proactive decision-making, facilitating timely development and commercialization efforts.

FAQs

1. How do patent expirations impact the availability of anti-anginal drugs?
Patent expirations open markets to generic competitors, reducing drug prices and increasing patient access. However, they also challenge existing brands to innovate through new formulations or combinations to sustain market share.

2. What are the primary patent strategies employed by pharmaceutical companies in anti-anginal drugs?
Companies file for chemical, formulation, method-of-use, and combination patents to protect various aspects of their products, extending exclusivity. They may also employ patent thickets to deter generic entry.

3. Which anti-anginal drugs are currently under patent protection?
Novel agents like certain phosphodiesterase inhibitors, proprietary formulations of ranolazine, and combination FDCs retain active patent protection. Most traditional drugs, such as nitrates and early-generation beta-blockers, have expired patents.

4. How does the patent landscape influence drug pricing in the anti-anginal market?
Patented drugs command higher prices due to market exclusivity, while patent expirations lead to increased generic competition, significantly lowering prices and impacting profitability.

5. What future innovations could reshape the patent landscape for anti-anginal drugs?
Advancements in biologics, personalized medicine, and digital health tools may introduce new patent opportunities, creating more complex and extended patent protections in the future.

---

Sources:
[1] MarketResearch.com: Anti-Anginal Drugs Market Size & Trends (2021).
[2] FDA Patent Database and Public Patent Records.